Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 10/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 8/20 | 0.48 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.46 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.46 |
| ▸ | ITGAL | P20701 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831940 | 1.00 | ITGA4 (0.48) | ITGA4ITGB1ITGB7GPR34NHERF1 | |
| SCHEMBL4824030 | 0.92 | PYGL (0.48) | ITGA4ITGB1ITGB7PYGL | |
| SCHEMBL4824034 | 0.92 | PYGL (0.48) | ITGA4ITGB1ITGB7PYGL | |
| SCHEMBL3991444 | 0.90 | ITGA4 (0.48) | ITGA4ITGB1ITGB7GPR34NHERF1 | |
| SCHEMBL5927011 | 0.90 | ITGA4 (0.48) | ITGA4ITGB1ITGB7GPR34NHERF1 | |
| SCHEMBL5926194 | 0.87 | ITGA4 (0.46) | ITGA4ITGB1ITGB7GPR34NHERF1 | |
| SCHEMBL5927216 | 0.86 | ITGA4 (0.49) | ITGA4ITGB1ITGB7GPR34ERAP1 | |
| SCHEMBL5927573 | 0.86 | ITGA4 (0.45) | ITGA4ITGB1ITGB7GPR34ERAP1 | |
| SCHEMBL5926619 | 0.86 | ITGA4 (0.47) | ITGA4ITGB1ITGB7GPR34KIFC1 | |
| SCHEMBL5926298 | 0.86 | ITGA4 (0.47) | ITGA4ITGB1ITGB7GPR34ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | ITGA4 3968/4885ITGB1 3853/4885ITGB7 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.